Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:111
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 111
Character Range: 67559–68745

111   Vaccine                                                                                                                                                                                                                                                                                Synflorix          Injection (0.5mL)                                                                 Polysaccharides of Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F conjugated to protein D (a surface protein from non‑typeable Haemophilus influenzae), serotype 18C conjugated to tetanus toxoid protein and serotype 19F conjugated to diptheria toxoid protein – 1 µg of each 1, 4, 6B, 7F, 9V, 14 and 23F and 3 µg of 4, 18C and 19F.  4 dose
      Pneumococcal (conjugate, 10‑valent)

      Circumstances
      Vaccine may be provided to:
       (a) a child who is about 2, 4, 6 or 18 months old; or
       (b) to a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab.